GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - ARCTURUS THERAPEUTICS HOLDINGS INC

Financial Performance:

• No specific revenue, earnings, or cash flow figures disclosed; company remains in clinical development with no commercial products generating sales (aside from past COVID vaccine technology licensing).
• Potential $40 million funding milestone triggered by Thermo Fisher Therapeutics if Arcturus proceeds to Phase 3 for its Cystic Fibrosis (CF) program.
• No specific debt or balance sheet metrics detailed in the transcript; focus is on capital-efficient clinical progression and milestone triggers.

Guidance and Future Outlook:

• Q2 2027: Full data presentation for the fourth cohort of Phase 2 Cystic Fibrosis (CF) trial (ARCT-150).
• Early 2027: Anticipated initiation of clinical trials for the reformulated OTC deficiency asset (ARCT-2601).
• H2 2027: Expected top-line data for the ARCT-2601 OTC deficiency program.
• H2 2027: IND submission expected for the new Phenylketonuria (PKU) pipeline candidate.
• Management aims for a "full data presentation" in Q2 2027 rather than immediate top-line releases, though top-line data may be shared earlier if the decision to advance to Phase 3 is made (motivated by the $40M milestone).

Business Segments and Product Lines:

• Cystic Fibrosis (CF): Inhaled mRNA therapeutic (ARCT-150) targeting Class 1 mutations (patients with no functional CFTR protein, ~15% of CF patients, up to 40% in specific regions like Turkey/Israel).
  • Current Phase 2 cohort enrolls 20 patients; enrollment completion expected by end of calendar year.
  • Study updated to include patients with 45-85% predicted lung function (lowering the ceiling and raising the floor from prior cohorts) to better detect clinical signals.
  • Endpoints include lung clearance index, high-resolution CT scans, and quality of life, in addition to spirometry (FEV1).
• Ornithine Transcarbamylase (OTC) Deficiency: Intravenous mRNA therapeutic (ARCT-2601) reformulated with Lunar 2.0 technology.
  • Successfully normalizes both ammonia and glutamine levels (unlike current standard of care which only controls ammonia).
  • Goal: Shift from bi-weekly 3-hour hospital visits to monthly, lower-dose home administration.
  • Designated as a "featured program" with high likelihood of success, potentially becoming the standard of care for the #1 urea cycle disorder.
• New Indication (PKU): Phenylketonuria added to pipeline; Lunar 2.0 enables dosing regimens previously considered intractable.
• Platform Technology:
  • Lunar 2.0: Next-gen lipid nanoparticle technology demonstrated to be 38 times more potent than Lunar 1.0 in non-human primates.
  • Enables convenience, lower dosing, and broader therapeutic scope (liver targets including OTC and PKU).

Market and Competitive Landscape:

• CF: Differentiated from modulator-based competitors (e.g., Vertex) by treating "Class 1" patients who lack a transporter entirely rather than fixing a broken one; significant unmet need in this subset.
• OTC Deficiency: Addresses the #1 urea cycle disorder; current market relies on ammonia scavengers that fail to control glutamine, creating a clear differentiation opportunity.
• Competitive Advantage: Management draws parallels to Alnylam's 2012 shift from D-Lin-MDMA to Lipid MC3, suggesting potential for significant enterprise value creation upon validation of Lunar 2.0.
• Market Opportunity: OTC program identified as a multi-billion dollar peak potential opportunity; potential to be a number one player in the urea cycle disorder space.

Risks and Challenges:

• Clinical Trial Execution: Need to avoid statistical noise caused by variable baseline spirometry performance (addressed in Protocol 4 by tightening quality control and patient selection).
• Regulatory Path: Requires FDA engagement to confirm the pivotal trial path for both stable adults and pediatric populations in OTC deficiency.
• Patient Demographics: High prevalence of Class 1 CF in specific regions (Turkey, Israel) requires targeted geographic enrollment; variability in patient lung function could impact data interpretation.
• Development Timeline: Heavy concentration of catalysts scheduled for 2027 creates a dependency on successful execution in the next 12-24 months.

Management Commentary and Tone:

• Tone: Highly confident and optimistic, particularly regarding the OTC program ("no longer a dark horse," "featured program").
• Strategic Focus: Emphasizes the transformative potential of Lunar 2.0 to enable new targets and convenience.
• Team Confidence: CEO and CMO display strong conviction in the 2027 catalyst sequence, describing it as the "fruits of 12 years of labor."
• Community Engagement: Notes strong support from the CF Foundation and regulatory agencies for the CF program, highlighting a desire for a novel treatment in this severe class.

Analyst Questions and Answers:

• CF Enrollment & Timeline: Analysts questioned enrollment speed; Management confirmed active enrollment through year-end with no specific date for top-line data, only a Q2 2027 full data presentation.
• CF Patient Selection: Explained strategy to lower the lung function ceiling (to 85%) and raise the floor (to 45%) to maximize signal detection, addressing prior issues with "normal" lungs in early cohorts.
• CF Go/No-Go Decision: Clarified that Phase 3 advancement triggers the $40M milestone; decision will be based on collective data (CT scans, LCQI, FEV1) rather than a single metric.
• OTC Efficacy: Confirmed normalization of both ammonia and glutamine in the first-gen product; Lunar 2.0 aims to reduce dose and frequency while maintaining efficacy.
• Lunar 2.0 Validation: Addressed the significance of 6-primate data; management asserts this small cohort is sufficient for FDA discussion on pivotal trial design.
• Phase 3 Efficiency: Expressed confidence that Phase 3 for CF will be less time-consuming and expensive due to insights from the REACH natural history study data.

Other Key Points:

• PKU Strategy: Phenylketonuria is now a viable target only due to the potency of Lunar 2.0; previous mRNA attempts failed due to frequent dosing requirements.
• OTC Disease Biology: Highlights the X-linked nature of OTC (females often stable, males often dying), allowing for distinct pivotal trial strategies for adults vs. pediatrics.
• Commercial Path: ARCT-2601 aims to transition from hospital infusion to nurse-administered home care, significantly improving patient quality of life.
• Valuation Narrative: Management explicitly frames the Lunar 2.0 validation in OTC as a catalyst for significant market re-rating, similar to historical biotech inflection points.